Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-07-20
    E.g., 2018-07-20

Articles

26728 items
8:05 AM, Jun 29, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Galapagos reports CF data, provides update on AbbVie partnership

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) reported that GLPG2737 failed to significantly improve lung function in the Phase II PELICAN trial to treat cystic fibrosis. The company also said partner AbbVie Inc. (NYSE:ABBV) has scrapped plans for...
8:04 AM, Jun 29, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Summit discontinues DMD program after Phase II miss

Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT) discontinued development of ezutromid (SMT C1100) after the candidate failed in the Phase II PhaseOut DMD trial to treat Duchenne muscular dystrophy (DMD). PhaseOut DMD enrolled 40 DMD patients ages 5-10....
8:01 AM, Jun 29, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

AZ and Merck's Lynparza meets in Phase III for first-line ovarian cancer

AstraZeneca plc (LSE:AZN; NYSE:AZN) and partner Merck & Co. Inc. (NYSE:MRK) said Lynparza olaparib as a first-line maintenance therapy improved progression-free survival (PFS) vs. placebo in patients with BRCA-mutated advanced ovarian cancer, meeting the primary...
7:54 AM, Jun 29, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Sophiris reports patient death in prostate cancer trial

Sophiris Bio Inc. (NASDAQ:SPHS) reported a patient death in an open-label, U.S. and U.K. Phase IIb trial evaluating topsalysin (PRX302) to treat localized prostate cancer. The company said it is evaluating the cause of death. The...
7:53 AM, Jun 29, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Cara's IV analgesic meets in Phase III for postoperative pain

Cara Therapeutics Inc. (NASDAQ:CARA) said IV CR845 met the primary and secondary endpoints in the adaptive Phase II/III CLIN3001 trial to treat postoperative pain in patients undergoing abdominal surgery. On the primary endpoint, the 1 µg/kg...
7:48 AM, Jun 29, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Zafgen's ZGN-1061 meets in Phase II for Type II diabetes

Zafgen Inc. (NASDAQ:ZFGN) said the 0.9 mg dose of subcutaneous ZGN-1061 every three days met the primary endpoint in a Phase II trial to treat Type II diabetes in patients failing multiple other antidiabetic agents....
7:46 AM, Jun 29, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Arsanis discontinues Phase II of lead anti-infective

Arsanis Inc. (NASDAQ:ASNS) discontinued a double-blind, international Phase II trial of lead candidate ASN100 to prevent Staphylococcus aureus pneumonia after a futility analysis showed that the candidate was unlikely to meet its primary endpoint. In a...
7:46 AM, Jun 29, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Aquinox discontinues development of rosiptor

Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) said its sole clinical asset, rosiptor (AQX-1125), missed the primary endpoint in the double-blind, international Phase III LEADERSHIP 301 trial to treat interstitial cystitis/bladder pain syndrome (IC/BPS). The company said it...
7:45 AM, Jun 29, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Global Blood reports Phase III sickle cell data that could support accelerated approval of voxelotor

Global Blood Therapeutics Inc. (NASDAQ:GBT) reported data from Part A of the Phase III HOPE trial that it believes could support accelerated approval of voxelotor (formerly GBT440) to treat sickle cell disease. The company said voxelotor...
7:29 AM, Jun 29, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Tecentriq meets endpoints in Phase III for extensive-stage SCLC

Roche (SIX:ROG; OTCQX:RHHBY) said first-line treatment with Tecentriq atezolizumab plus chemotherapy met the co-primary endpoints of improving overall survival (OS) and progression-free survival (PFS) compared with chemotherapy alone in the Phase III IMpower133 trial to...

Pages